Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on X:
“Antibody-Drug Conjugates (ADCs) in SCLC.
All active agents in 2L/3L+ setting – DLL3, B7-H3, SEZ6, TROP2 – summarized in one slide.
Includes payloads, companies, trials, ORR/PFS/OS, and toxicity profile
Which one do you think is the most promising one?
Don’t confuse this with Tarlatamab. That’s BiTE and Not ADC.”
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared his post on X, adding:
“Now just to compare BiTE Tarlatamab vs ADCs in SCLC.”
More posts featuring Amol Akhade.
